Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 45Lymphoma, Large B-Cell, Diffuse 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Burkitt Lymphoma 22Neuroblastoma 20Leukemia 20Lymphoma, Non-Hodgkin 19Sarcoma 12Multiple Myeloma 12Lymphoma, Follicular 12Central Nervous System Neoplasms 12HIV Infections 11Hodgkin Disease 10Lymphoma, Large-Cell, Immunoblastic 9Acquired Immunodeficiency Syndrome 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Mantle-Cell 8Leukemia, Lymphocytic, Chronic, B-Cell 7Neuroectodermal Tumors, Primitive, Peripheral 6Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Anaplastic 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Leukemia, Biphenotypic, Acute 5Sarcoma, Kaposi 4Sarcoma, Ewing 4Rhabdomyosarcoma 4Neoplasms 4Lymphoma, T-Cell 4Dendritic Cell Sarcoma, Interdigitating 4

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Vincristine × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡